2022
Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis.
Donatelle M, Agasthi P, Parise H, Igyarto Z, Martinsen B, Leon M, Beohar N. Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis. Journal Of Invasive Cardiology 2022, 34: e696-e700. PMID: 36200995, DOI: 10.25270/jic/22.00066.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisNon-AS cohortAortic stenosisNon-AS patientsSuccessful stent placementOrbital atherectomyStent placementOA useHospital major adverse cardiovascular eventsSevere calcific coronary artery diseaseCalcific coronary artery diseaseConcomitant severe aortic stenosisMajor adverse cardiovascular eventsCoronary orbital atherectomyIdeal revascularization strategyAdverse cardiovascular eventsMount Sinai Medical CenterProspective randomized trialsGlomerular filtration rateCoronary artery diseaseSinai Medical CenterPaucity of dataAngiographic complicationsMACE rateCardiovascular eventsCoronary orbital atherectomy treatment of Hispanic and Latino patients: A real‐world comparative analysis
Beohar N, Stone G, Martinsen B, Parise H, Vinardell J, Heimowitz T, Koelbl C, Leon M, Kirtane A. Coronary orbital atherectomy treatment of Hispanic and Latino patients: A real‐world comparative analysis. Catheterization And Cardiovascular Interventions 2022, 99: 1752-1757. PMID: 35312163, PMCID: PMC9540752, DOI: 10.1002/ccd.30158.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsNon-HL groupNon-HL patientsHL patientsLatino patientsHigh prevalenceRetrospective analysisHL groupLargest real-world experienceReal-world comparative analysesCoronary artery calcium scoreOrbital atherectomy treatmentAdverse cardiac eventsArtery calcium scoreMount Sinai Medical CenterPercutaneous coronary interventionCardiovascular disease mortalityHigh-risk populationOverall mean ageSinai Medical CenterClinical trial researchElectronic health recordsAngiographic complicationsAtherectomy useOA use
2016
Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial
Costa R, Abizaid A, Mehran R, Schofer J, Schuler G, Hauptmann K, Magalhães M, Parise H, Grube E, Investigators B. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovascular Interventions 2016, 9: 51-64. PMID: 26762911, DOI: 10.1016/j.jcin.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsFemaleGermanyHumansKaplan-Meier EstimateMaleMiddle AgedNeointimaPaclitaxelPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSingle-Blind MethodSirolimusStainless SteelSurface PropertiesTime FactorsTreatment OutcomeConceptsStent late lumen lossPaclitaxel-eluting stentsLate lumen lossDrug-coated stentsStent thrombosisBiolimus A9First-generation paclitaxel-eluting stentsDe novo coronary lesionsMajor adverse cardiac eventsPolymer-free biolimus A9Probable stent thrombosisAdverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationClinical event ratesLong-term outcomesLesion revascularizationAngiographic followCardiac eventsClinical outcomesCoronary lesionsLesions 4Lumen lossStandard doseStainless steel platform
2011
Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus
Stone G, Kedhi E, Kereiakes D, Parise H, Fahy M, Serruys P, Smits P. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation 2011, 124: 893-900. PMID: 21824922, DOI: 10.1161/circulationaha.111.031070.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionEverolimus-eluting stentsDiabetes mellitusLesion revascularizationCoronary interventionStent thrombosisMyocardial infarctionStent typeIschemia-driven target lesion revascularizationEnd pointDifferential clinical responseXIENCE V EverolimusEfficacy end pointTarget lesion revascularizationTreatment of patientsCoronary stent systemSignificant differencesEverolimus-ElutingCoronary revascularizationEfficacy outcomesClinical responseDiabetic statusDiabetic patientsClinical outcomes